Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response
Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response
复制标题
DOI：
10.1038/sj.bmt.1702830
复制
发表时间：
2001-03-01
影响因子：
4.8
通讯作者：
Henslee-Downey, PJ
中科院分区：
文献类型：
--
作者：
Lamb, LS;Musk, P;Henslee-Downey, PJ
难治性急性淋巴细胞白血病(ALL)通常是无法治愈的，异基因骨髓移植(BMT)后的复发率仍然很高。我们已经报道，骨髓移植后不久患者的Gamma Delta(+)T细胞数量增加的患者复发的可能性显著降低，我们现在在七对供者/受者对中显示，供者来源的V Delta1(+)CD4(-)CD8(-)Gamma Delta(+)T细胞被激活和增殖，以响应受者的初级ALL母细胞，此外，这些细胞已被证明结合和溶解受者的所有母细胞，单独地，Gamma Delta(+)T细胞在混合淋巴细胞培养中增殖很差或根本不增殖，对抗HLA不匹配的无关刺激细胞。这些观察结果表明，异基因伽马增量(+)T细胞可能是一种有效的免疫治疗策略，可用于治疗难治性疾病，而不存在移植物抗宿主病的风险。
Refractory acute lymphoblastic leukemia (ALL) is often incurable, and relapse rates following allogeneic bone marrow transplantation (BMT) remain high. We have reported that patients who develop increased numbers of gamma delta (+) T cells soon after BMT are significantly less likely to relapse, We now show in seven donor/recipient pairs that donor-derived V delta1(+)CD4(-)CD8(-)gamma delta (+) T cells are activated and proliferate in response to recipient primary ALL blasts, In addition, these cells have been shown to bind and lyse the recipient ALL blasts, Separately, gamma delta (+) T cells proliferate poorly or not at all in mixed lymphocyte culture against HLA-mismatched unrelated stimulator cells. These observations suggest that allogeneic gamma delta (+) T cells could be an effective immunotherapeutic strategy against refractory disease without the risk of graft-versus-host disease.